By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic testing firm Signal Genetics has agreed to buy molecular diagnostics company ChipDx for an undisclosed amount.

Under the terms of the deal announced today, Signal will acquire all of ChipDx's assets, including its patents for its prognostic tests for lung, breast, and colon cancers. It is buying BreastGeneDX, ColonGeneDX, and LungGeneDX, as well as all diagnostic and prognostic tests under development by ChipDx.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.